Eton Pharmaceuticals (NASDAQ:ETON) Rating Increased to Buy at Wall Street Zen

Eton Pharmaceuticals (NASDAQ:ETON) was upgraded by equities research analysts at Wall Street Zen from a “hold” rating to a “buy” rating in a research report issued on Saturday.

ETON has been the subject of a number of other reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Thursday, January 22nd. Zacks Research raised Eton Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Thursday, January 1st. HC Wainwright upped their price objective on shares of Eton Pharmaceuticals from $37.00 to $52.00 and gave the stock a “buy” rating in a research report on Friday. Craig Hallum increased their price objective on shares of Eton Pharmaceuticals from $30.00 to $35.00 and gave the stock a “buy” rating in a research note on Friday. Finally, B. Riley Financial raised their target price on shares of Eton Pharmaceuticals from $26.00 to $31.00 and gave the company a “buy” rating in a report on Friday. Three investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat, Eton Pharmaceuticals currently has an average rating of “Hold” and a consensus target price of $39.33.

Eton Pharmaceuticals Stock Up 7.5%

NASDAQ ETON opened at $22.32 on Friday. The company has a current ratio of 1.63, a quick ratio of 1.25 and a debt-to-equity ratio of 1.19. The company has a market cap of $598.58 million, a price-to-earnings ratio of -123.99 and a beta of 1.19. The company has a 50 day moving average of $16.72 and a 200-day moving average of $17.38. Eton Pharmaceuticals has a 1-year low of $11.09 and a 1-year high of $23.00.

Eton Pharmaceuticals (NASDAQ:ETON) last issued its quarterly earnings results on Thursday, March 19th. The company reported $0.05 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.12 by ($0.07). Eton Pharmaceuticals had a negative return on equity of 2.66% and a negative net margin of 5.75%.The company had revenue of $21.28 million for the quarter, compared to analyst estimates of $20.58 million. On average, equities research analysts expect that Eton Pharmaceuticals will post -0.14 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Eton Pharmaceuticals

Several hedge funds have recently modified their holdings of ETON. Caitong International Asset Management Co. Ltd acquired a new position in Eton Pharmaceuticals in the 4th quarter worth about $50,000. Invesco Ltd. raised its position in Eton Pharmaceuticals by 46.1% in the fourth quarter. Invesco Ltd. now owns 19,691 shares of the company’s stock valued at $333,000 after purchasing an additional 6,213 shares during the last quarter. XTX Topco Ltd boosted its stake in shares of Eton Pharmaceuticals by 33.3% during the fourth quarter. XTX Topco Ltd now owns 32,527 shares of the company’s stock valued at $550,000 after purchasing an additional 8,128 shares in the last quarter. Millennium Management LLC grew its holdings in shares of Eton Pharmaceuticals by 400.1% during the fourth quarter. Millennium Management LLC now owns 79,331 shares of the company’s stock worth $1,341,000 after purchasing an additional 63,469 shares during the last quarter. Finally, Jump Financial LLC bought a new stake in shares of Eton Pharmaceuticals during the fourth quarter worth about $178,000. Institutional investors and hedge funds own 27.86% of the company’s stock.

More Eton Pharmaceuticals News

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Several brokerages raised price targets and reiterated buy ratings (HC Wainwright to $52, B. Riley to $31, Craig Hallum to $35), increasing upside expectations and driving bullish investor sentiment. Analyst Upgrades
• Positive Sentiment: Eton acquired U.S. rights to HEMANGEOL, expanding its commercial portfolio in a specialty/rare-disease area and creating a clearer near-term revenue pathway. Eton Pharmaceuticals Acquires U.S. Rights to HEMANGEOL
• Positive Sentiment: Market commentary highlights a meaningful consensus upside — Zacks notes analysts’ mean targets imply roughly a 49% rally — reinforcing the bullish narrative from upgraded targets. Does Eton Pharmaceuticals Have the Potential to Rally 49.25%?
• Neutral Sentiment: Earnings call and company commentary emphasized record revenue growth and commercial progress, which supports the growth story but did not fully offset margin pressures. Q4 2025 Earnings Call Summary
• Neutral Sentiment: Reported short-interest data for March appears anomalous/flat (0 shares reported and a 0.0 days-to-cover), so it’s unlikely to be a material driver of today’s move. (Data looks unreliable.)
• Negative Sentiment: Q4 results: revenue beat slightly ($21.28M vs. $20.58M est.) but EPS missed ($0.05 vs. $0.12 est.); the company still reports negative net margin and negative ROE, raising profitability concerns. Eton Pharmaceuticals Reports Q4 & Full-Year 2025 Results
• Negative Sentiment: Analyst coverage also flagged the EPS miss in headlines (Zacks: earnings lag estimates), which could cap near-term sentiment until margins improve. Eton Q4 Earnings Lag Estimates

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.